High Early Death Rates, Treatment Resistance and Short Survival of Black Adolescent and Young Adults with Acute Myeloid Leukemia

2021 ◽  
Author(s):  
Karilyn T. Larkin ◽  
Deedra Nicolet ◽  
Benjamin J. Kelly ◽  
Krzysztof Mrózek ◽  
Stephanie LaHaye ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Young Adults ◽  
Myeloid Leukemia ◽  
Treatment Resistance ◽  
Early Death ◽  
Death Rates ◽  
Short Survival ◽  
Black Adolescent ◽  
Adolescent And Young Adults ◽  
Acute Myeloid

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry

Blood ◽  
2009 ◽  
Vol 113 (18) ◽  
pp. 4179-4187 ◽  
Author(s):  
Gunnar Juliusson ◽  
Petar Antunovic ◽  
Åsa Derolf ◽  
Sören Lehmann ◽  
Lars Möllgård ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Intensive Therapy ◽  
Early Death ◽  
The Elderly ◽  
Intensive Treatment ◽  
Real World Data ◽  
Death Rates ◽  
Acute Myeloid

AbstractAcute myeloid leukemia (AML) is most common in the elderly, and most elderly are thought to be unfit for intensive treatment because of the risk of fatal toxicity. The Swedish Acute Leukemia Registry covers 98% of all patients with AML (nonacute promyelocytic leukemia) diagnosed in 1997 to 2005 (n = 2767), with a median follow-up of 5 years, and reports eligibility for intensive therapy, performance status (PS), complete remission rates, and survival. Outcomes were strongly age and PS dependent. Early death rates were always lower with intensive therapy than with palliation only. Long-term survivors were found among elderly given intensive treatment despite poor initial PS. Total survival of elderly AML patients was better in the geographic regions where most of them were given standard intensive therapy. This analysis provides unique real world data from a large, complete, and unselected AML population, both treated and untreated, and gives background to treatment decisions for the elderly. Standard intensive treatment improves early death rates and long-term survival compared with palliation. Most AML patients up to 80 years of age should be considered fit for intensive therapy, and new therapies must be compared with standard induction.

Prognostic value of genetic mutations in adolescent and young adults with acute myeloid leukemia

2017 ◽  
Vol 107 (2) ◽  
pp. 201-210 ◽  
Author(s):  
Yachiyo Kuwatsuka ◽  
Daisuke Tomizawa ◽  
Rika Kihara ◽  
Yasunobu Nagata ◽  
Norio Shiba ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Young Adults ◽  
Myeloid Leukemia ◽  
Prognostic Value ◽  
Genetic Mutations ◽  
Adolescent And Young Adults ◽  
Acute Myeloid

scholarly journals Predictors of Early Death and Survival Among Children, Adolescents and Young Adults with Acute Myeloid Leukemia in California, 1988-2011: A Population-Based Study

Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 1323-1323 ◽  
Author(s):  
Renata Abrahão ◽  
Ruth H Keogh ◽  
Daphne Y Lichtensztajn ◽  
Rafael Marcos-Gragera ◽  
Bruno C. Medeiros ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Young Adults ◽  
Myeloid Leukemia ◽  
Early Death ◽  
Adolescents And Young Adults ◽  
Cell Transplant ◽  
Clinical Factors ◽  
Cancer Centers ◽  
Factors Associated ◽  
Acute Myeloid

Abstract Background A better understanding of factors associated with early death and survival may guide future health policy aimed at improving outcomes among children, adolescents and young adults with acute myeloid leukemia (AML). Methods We examined trends in early death and survival among 3,935 patients aged 0-39 years diagnosed with de novo AML in California during 1988-2011. We estimated overall survival and applied logistic and Cox regression to evaluate the association between sociodemographic and selected clinical factors with early death and survival. Results There was a trend towards decline in early death from 9.7% in 1988-1995 to 7.1% in 2004-2011 (P=0.062). Survival improved substantially over time, but 5-year survival was still only 50% (95% CI 47%-53%) even in the most recent calendar period. Overall, the main factors associated with poor outcomes were older age at diagnosis, treatment at hospitals not affiliated with National Cancer Institute (NCI)-designated cancer centers, and black race/ethnicity. For patients diagnosed during 1996-2011, survival was lower for patients without health insurance and those who did not receive a hematopoietic stem cell transplant (HSCT). The association between survival and sociodemographic and clinical factors were stronger among patients aged 30-39 years. Conclusions Mortality after AML remained strikingly high and increased with age. To improve outcomes, strategies may include wider insurance coverage, treatment at hospitals affiliated with NCI-designated cancer centers and access to HSCT for high-risk patients. Collaborative clinical trials aimed to evaluate the efficacy and toxicity of novel agents for each subtype of disease are warranted. Disclosures No relevant conflicts of interest to declare.

scholarly journals Extramedullary acute myeloid leukemia presenting in young adults demonstrates sensitivity to high-dose anthracycline: a subset analysis from ECOG-ACRIN 1900

Haematologica ◽  
2018 ◽  
Vol 104 (4) ◽  
pp. e147-e150 ◽  
Author(s):  
Hugo F. Fernandez ◽  
Zhuoxin Sun ◽  
Mark R. Litzow ◽  
Selina M. Luger ◽  
Elisabeth Paietta ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Young Adults ◽  
Myeloid Leukemia ◽  
High Dose ◽  
Subset Analysis ◽  
Acute Myeloid
Sign in / Sign up

Export Citation Format

Share Document